Trial Profile
Follow-up survey of nivolumab, pembrolizumab and ipilimumab in Sapporo City General Hospital
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions
- 30 Sep 2019 Status changed from active, no longer recruiting to completed.
- 08 Oct 2018 New trial record